Evidence map›Paper›PMID 42111195›Full record

ArticleiScience2026

Multiple sclerosis-associated HLA demarcates EBV-specific CD8

Sanne Reijm, Ana M Marques, Jasper Rip, Cato E A Corsten, Annet F Wierenga-Wolf, Harm de Wit, Marie-José Melief, Yifan van Hasselt, Jamie van Langelaar, Rinze Neuteboom and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sanne ReijmDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Ana M MarquesDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jasper RipDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Cato E A CorstenMS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Annet F Wierenga-WolfDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Harm de WitDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Marie-José MeliefDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Yifan van HasseltDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jamie van LangelaarDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Rinze NeuteboomMS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Beatrijs H A WokkeMS Center ErasMS, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Yvonne M MuellerDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Joost SmoldersDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Marvin M van LuijnDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In multiple sclerosis (MS), T cells could contribute to disease in their attempt to control the Epstein-Barr virus (EBV). Here, we compared the presence of HLA-B7 (higher MS risk) or HLA-A2 (lower MS risk) and investigated the effector phenotype of EBV epitope-specific CD8

Indexed as

immunology

Identifiers

PMID42111195
PMCPMC13157025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.